Vericel Corporation (VCEL)

In the past six months, Vericel's stock experienced notable events. As of May 1, 2026, the stock price was $35.56, within a 52-week range of $28.95 - $45.97. The stock decreased by 7.1% from the beginning of 2026 to $33.46 as of May 9, 2026. On May 7, 2026, Vericel reported strong first-quarter 2026 financial results, with total revenue increasing 30% year-over-year to $68.4 million, surpassing forecasts. The company also announced a ten-year agreement with BARDA valued at up to $196.9 million for the procurement and advanced development of NexoBrid.

Demand for Vericel's products, particularly MACI, is subject to seasonality, with stronger orthopedic volumes typically in the second half of the year. Demand for Epicel and NexoBrid in burn care is influenced by patient incidence, which can be episodic, and by factors such as BARDA contracts and preparedness stockpiles for NexoBrid. Vericel expects to continue experiencing this seasonality effect in subsequent years.

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing, manufacturing, and marketing advanced autologous cell therapies for sports medicine and severe burn care. Their business centers on patient-specific expanded cellular therapies and specialty biologics designed to repair injuries and restore lives. Key products include MACI, an autologous chondrocyte implant for knee cartilage repair; Epicel, a permanent skin replacement therapy for severe burns; and NexoBrid, a topical enzymatic product for eschar removal in burns, for which Vericel holds North American commercial rights.

Vericel's commercial operations are primarily in the United States, with over 95% of revenue from domestic sales. MACI and Epicel are FDA-approved and commercialized domestically, and NexoBrid has also entered the U.S. market after FDA approval in 2023. The company is seeking partners to commercialize MACI and Epicel outside the U.S., but direct international sales are limited. The company's headquarters are located in Cambridge, Massachusetts.

Vericel's brand reputation appears positive, driven by its innovative cell therapies and strong financial performance. The company is recognized as a leader in the cartilage repair market due to MACI and holds a strong position in severe burn care with Epicel and NexoBrid. Key events positively impacting its reputation include FDA approval for MACI Arthro, strong financial performance, the strategic BARDA agreement, and FDA approval for MACI commercial manufacturing at a new facility. There is no readily available information indicating significant negative events affecting Vericel's brand reputation in the past year.

Vericel Corporation's ownership is predominantly held by institutional investors, who held approximately 75,008,654 shares as of August 20, 2025. Major institutional shareholders include BlackRock, Inc., The Vanguard Group, Inc., and State Street Corp. Insider ownership is relatively small, around 1.06% to 8.90% of the stock. Consonance Capital Management LP is a significant individual shareholder, owning 4.40% of the company. Over the past three months (prior to May 8, 2026), insiders sold approximately $2 million worth of shares, with no reported purchases.